Abiraterone acetate
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ABIRATERONE |
|---|---|
| Type | Drug |
| Aliases | YonsaZytigaАбіратерон |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Androgen biosynthesis inhibitor (CYP17A1) |
|---|---|
| Mechanism | Selective irreversible CYP17A1 inhibitor — blocks adrenal and intratumoral androgen synthesis (testosterone, DHT precursors). Always combined with low-dose corticosteroid (prednisone) to mitigate mineralocorticoid excess (hypertension, hypokalemia, fluid retention). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Workhorse ARPI for mHSPC LATITUDE-high-risk and mCRPC 1L. Always co-administer prednisone — mineralocorticoid syndrome from CYP17 blockade is serious.
Used By
Regimens
REG-ADT-ABIRATERONE- ADT + abiraterone + prednisone (continuous)